« Literature Evaluations for Biological Safety | Main | Risk-Based Monitoring—The New FDA Guidance »

13 November 2011


Erica Heath

You said..."But start-up medical device companies have never monitored as heavily as the guidance assumes and, in that sense, the principles risk-based monitoring won't save on monitoring costs."

I agree. Drug company monitoring is typically very different from device company monitoring. There are a number of reasons but your point that the guidance cannot be equally applied is very well taken.

The comments to this entry are closed.